Strs Ohio cut its position in Masimo Corp. (NASDAQ:MASI) by 11.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,100 shares of the company’s stock after selling 3,100 shares during the period. Strs Ohio’s holdings in Masimo Corp. were worth $1,265,000 as of its most recent filing with the SEC.
Several other hedge funds have also bought and sold shares of MASI. Mitra Capital LLC acquired a new stake in Masimo Corp. during the first quarter worth $4,387,000. Adams Diversified Equity Fund Inc. acquired a new stake in Masimo Corp. during the second quarter worth $530,000. First Republic Investment Management Inc. acquired a new stake in Masimo Corp. during the first quarter worth $12,638,000. Bellevue Group AG acquired a new stake in Masimo Corp. during the first quarter worth $3,138,000. Finally, Zebra Capital Management LLC increased its stake in Masimo Corp. by 20.9% in the first quarter. Zebra Capital Management LLC now owns 21,916 shares of the company’s stock worth $917,000 after buying an additional 3,783 shares during the period. Hedge funds and other institutional investors own 79.88% of the company’s stock.
Shares of Masimo Corp. (NASDAQ:MASI) traded up 0.44% during trading on Wednesday, reaching $58.92. 248,091 shares of the company traded hands. The stock has a market capitalization of $2.91 billion, a PE ratio of 30.90 and a beta of 0.70. Masimo Corp. has a 52 week low of $33.03 and a 52 week high of $60.81. The firm has a 50 day moving average of $59.19 and a 200 day moving average of $51.84.
Masimo Corp. (NASDAQ:MASI) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.16. The business had revenue of $172.64 million for the quarter, compared to the consensus estimate of $166.02 million. Masimo Corp. had a net margin of 15.40% and a return on equity of 29.07%. The company’s revenue was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $0.36 earnings per share. On average, equities analysts predict that Masimo Corp. will post $2.02 EPS for the current year.
MASI has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Masimo Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 4th. BTIG Research reiterated a “hold” rating on shares of Masimo Corp. in a report on Friday, August 5th. Wedbush reiterated an “outperform” rating and set a $63.00 price target (up from $60.00) on shares of Masimo Corp. in a report on Thursday, August 4th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $55.00 price target (up from $52.00) on shares of Masimo Corp. in a report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Masimo Corp. presently has a consensus rating of “Buy” and a consensus price target of $52.60.
In other news, insider Rick Fishel sold 22,000 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $53.85, for a total value of $1,184,700.00. Following the transaction, the insider now directly owns 42,022 shares of the company’s stock, valued at $2,262,884.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Sanford Fitch sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $53.48, for a total transaction of $160,440.00. Following the completion of the transaction, the director now directly owns 58,000 shares in the company, valued at $3,101,840. The disclosure for this sale can be found here. Company insiders own 16.60% of the company’s stock.
About Masimo Corp.
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Corp. (NASDAQ:MASI).
Receive News & Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related companies with MarketBeat.com's FREE daily email newsletter.